Retina (Philadelphia, Pa.) · 2026
TRENDS IN THE MANAGEMENT OF PROLIFERATIVE DIABETIC RETINOPATHY IN THE FIRST YEAR AFTER DIAGNOSIS.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Charles, Bhatnagar Anshul, Ersan Sinan, Smiddy William E, Flynn Harry W, Williams Basil K
Аннотация
PURPOSE: To examine trends in initial treatment modality for patients diagnosed with proliferative diabetic retinopathy (PDR).
METHODS: A cross-sectional time series was performed between 2005 and 2024 using the TriNetX US Collaborative Network. Patients with new-onset PDR were identified, and initial treatment modality within one year after diagnosis was recorded. The proportion of patients managed with panretinal photocoagulation (PRP) monotherapy, antivascular endothelial growth factor (anti-VEGF) monotherapy, or combination therapy (PRP + anti-VEGF) were compared using Cochran-Armitage tests for trend. Rates of change in treatment proportionality were compared between 2005 to 2014 and 2015 to 2024, the time period before and after the publication of the Diabetic Retinopathy Clinical Research Network Protocol S.
RESULTS: A total of 14,768 patients with newly diagnosed PDR met inclusion criteria. In 2005, PRP monotherapy accounted for 100% of initial treatment. In 2024, combination therapy was the most commonly used treatment modality, accounting for 42.4% of cases (overall trend, P < 0.0001), followed by anti-VEGF monotherapy at 36.1% (overall trend, P < 0.0001), and PRP monotherapy at 21.5% (overall trend, P < 0.0001). After 2015, the annual rate of change differed significantly compared with the pre-2015 period for both monotherapies. The proportion of patients treated with PRP monotherapy showed a steeper relative annual decline (5.22% vs. 3.56% per year, P = 0.0338), while anti-VEGF monotherapy demonstrated a greater relative annual increase (2.03% vs. 1.58% per year, P = 0.0283).
CONCLUSION: Management of PDR has shifted over the past two decades from PRP monotherapy toward anti-VEGF therapy, including both combination therapy and monotherapy.
METHODS: A cross-sectional time series was performed between 2005 and 2024 using the TriNetX US Collaborative Network. Patients with new-onset PDR were identified, and initial treatment modality within one year after diagnosis was recorded. The proportion of patients managed with panretinal photocoagulation (PRP) monotherapy, antivascular endothelial growth factor (anti-VEGF) monotherapy, or combination therapy (PRP + anti-VEGF) were compared using Cochran-Armitage tests for trend. Rates of change in treatment proportionality were compared between 2005 to 2014 and 2015 to 2024, the time period before and after the publication of the Diabetic Retinopathy Clinical Research Network Protocol S.
RESULTS: A total of 14,768 patients with newly diagnosed PDR met inclusion criteria. In 2005, PRP monotherapy accounted for 100% of initial treatment. In 2024, combination therapy was the most commonly used treatment modality, accounting for 42.4% of cases (overall trend, P < 0.0001), followed by anti-VEGF monotherapy at 36.1% (overall trend, P < 0.0001), and PRP monotherapy at 21.5% (overall trend, P < 0.0001). After 2015, the annual rate of change differed significantly compared with the pre-2015 period for both monotherapies. The proportion of patients treated with PRP monotherapy showed a steeper relative annual decline (5.22% vs. 3.56% per year, P = 0.0338), while anti-VEGF monotherapy demonstrated a greater relative annual increase (2.03% vs. 1.58% per year, P = 0.0283).
CONCLUSION: Management of PDR has shifted over the past two decades from PRP monotherapy toward anti-VEGF therapy, including both combination therapy and monotherapy.